Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samit Ganguly

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Clinical Pharmacokinetics|October 7, 2021
Development and Evaluation of a Virtual Population of Children with Obesity for Physiologically Based Pharmacokinetic ModelingJacqueline G Gerhart, Fernando O Carreño, Andrea N Edginton, et al.
Antimicrobial Agents and Chemotherapy|March 20, 2013
In vitro and in vivo efficacy of β-lactams against replicating and slowly growing/nonreplicating Mycobacterium tuberculosisSuresh Solapure, Neela Dinesh, Radha Shandil, et al.
Bioanalysis|November 8, 2021
REGEN-COV<sup>®</sup> antibody cocktail bioanalytical strategy: comparison of LC-MRM-MS and immunoassay methods for drug quantificationSusan C Irvin, Samit Ganguly, Rachel Weiss, et al.
Frontiers in Immunology|March 26, 2026
The role of large immune complexes in anti-drug antibody development: a case study of anti-SARS-CoV-2 antibody therapeutics and co-administered mRNA vaccineSusan C Irvin, Zhiqiang Wang, Samit Ganguly, et al.
Clinical Pharmacology and Therapeutics|December 14, 2023
Subcutaneous Administration of Monoclonal Antibodies: Pharmacology, Delivery, Immunogenicity, and Learnings From Applications to Clinical DevelopmentJohn D Davis, Marçal Bravo Padros, Daniela J Conrado, et al.
The AAPS Journal|October 23, 2025
Association of Immunogenicity and Drug Exposure and the Importance of Target Engagement in ADA Development: A Clinical Case Study of Anti-SARS-CoV-2 BiotherapeuticsSusan C Irvin, Samit Ganguly, Zhiqiang Wang, et al.
Neurobiology of Pain (Cambridge, Mass.)|December 15, 2023
Monoclonal antibodies against GFRα3 are efficacious against evoked hyperalgesic and allodynic responses in mouse join pain models but, one of these, REGN5069, was not effective against pain in a randomized, placebo-controlled clinical trial in patients with osteoarthritis painSelin Somersan-Karakaya, Kenneth C Turner, Luz Cortes-Burgos, et al.
BMJ Open|October 9, 2024
Assessing the safety and pharmacokinetics of casirivimab and imdevimab (CAS+IMD) in a cohort of pregnant outpatients with COVID-19: results from an adaptive, multicentre, randomised, double-blind, phase 1/2/3 studyThomas D Norton, Mazhar Thakur, Samit Ganguly, et al.
Journal of the Pediatric Infectious Diseases Society|October 1, 2024
Safety and Pharmacokinetics of Casirivimab and Imdevimab (CAS + IMD) in Pediatric Outpatients With COVID-19Thomas D Norton, Mazhar Thakur, Samit Ganguly, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|July 5, 2022
Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19Flonza Isa, Eduardo Forleo-Neto, Jonathan Meyer, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Clinical Pharmacokinetics|October 7, 2021
Development and Evaluation of a Virtual Population of Children with Obesity for Physiologically Based Pharmacokinetic ModelingJacqueline G Gerhart, Fernando O Carreño, Andrea N Edginton, et al.
Antimicrobial Agents and Chemotherapy|March 20, 2013
In vitro and in vivo efficacy of β-lactams against replicating and slowly growing/nonreplicating Mycobacterium tuberculosisSuresh Solapure, Neela Dinesh, Radha Shandil, et al.
Bioanalysis|November 8, 2021
REGEN-COV<sup>®</sup> antibody cocktail bioanalytical strategy: comparison of LC-MRM-MS and immunoassay methods for drug quantificationSusan C Irvin, Samit Ganguly, Rachel Weiss, et al.
Frontiers in Immunology|March 26, 2026
The role of large immune complexes in anti-drug antibody development: a case study of anti-SARS-CoV-2 antibody therapeutics and co-administered mRNA vaccineSusan C Irvin, Zhiqiang Wang, Samit Ganguly, et al.
Clinical Pharmacology and Therapeutics|December 14, 2023
Subcutaneous Administration of Monoclonal Antibodies: Pharmacology, Delivery, Immunogenicity, and Learnings From Applications to Clinical DevelopmentJohn D Davis, Marçal Bravo Padros, Daniela J Conrado, et al.
The AAPS Journal|October 23, 2025
Association of Immunogenicity and Drug Exposure and the Importance of Target Engagement in ADA Development: A Clinical Case Study of Anti-SARS-CoV-2 BiotherapeuticsSusan C Irvin, Samit Ganguly, Zhiqiang Wang, et al.
Neurobiology of Pain (Cambridge, Mass.)|December 15, 2023
Monoclonal antibodies against GFRα3 are efficacious against evoked hyperalgesic and allodynic responses in mouse join pain models but, one of these, REGN5069, was not effective against pain in a randomized, placebo-controlled clinical trial in patients with osteoarthritis painSelin Somersan-Karakaya, Kenneth C Turner, Luz Cortes-Burgos, et al.
BMJ Open|October 9, 2024
Assessing the safety and pharmacokinetics of casirivimab and imdevimab (CAS+IMD) in a cohort of pregnant outpatients with COVID-19: results from an adaptive, multicentre, randomised, double-blind, phase 1/2/3 studyThomas D Norton, Mazhar Thakur, Samit Ganguly, et al.
Journal of the Pediatric Infectious Diseases Society|October 1, 2024
Safety and Pharmacokinetics of Casirivimab and Imdevimab (CAS + IMD) in Pediatric Outpatients With COVID-19Thomas D Norton, Mazhar Thakur, Samit Ganguly, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|July 5, 2022
Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19Flonza Isa, Eduardo Forleo-Neto, Jonathan Meyer, et al.
Pageof 3